
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Marcel van den Brink discloses the following relationships and financial interests:
-
DKMS
Fiduciary Role / Position; Professional Services and Activities -
Garuda Therapeutics
Professional Services and Activities -
GlaxoSmithKline
Professional Services and Activities (Uncompensated) -
Juno Therapeutics
Intellectual Property Rights
-
Pluto Immunotherapeutics
Equity; Professional Services and Activities -
Seres Therapeutics
Equity; Intellectual Property Rights; Professional Services and Activities -
Smart Immune SAS
Professional Services and Activities -
ThymoFox, Inc.
Equity
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
View all disclosures